Anna Laurell

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Kheir, Alaa; Johannsdottir, Berglind; Gronn-Weiss, Alexandra; Liu, Lisa L. et al.

Ingår i Acta Oncologica, s. 1355-1364, 2025

• DOI för Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab
• Ladda ner fulltext (pdf) av Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

Holmsten, Karin; Eknert, Johanna; Ofverholm, Elisabeth; Papantoniou, Dimitrios et al.

Ingår i Clinical Genitourinary Cancer, 2023

• DOI för Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
• Ladda ner fulltext (pdf) av Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

Lindberg, Åsa; Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne et al.

Ingår i Hematological Oncology, s. 23-31, 2022

• DOI för Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience
• Ladda ner fulltext (pdf) av Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres

Stenman, Maria; Staehler, Michael; Szabados, Bernadett; Sandström, Per et al.

Ingår i Acta Oncologica, s. 306-312, 2019

• DOI för Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres
• Ladda ner fulltext (pdf) av Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne; Laurell, Anna et al.

Ingår i Haematologica, 2018

• DOI för Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
• Ladda ner fulltext (pdf) av Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Kheir, Alaa; Johannsdottir, Berglind; Gronn-Weiss, Alexandra; Liu, Lisa L. et al.

Ingår i Acta Oncologica, s. 1355-1364, 2025

• DOI för Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab
• Ladda ner fulltext (pdf) av Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab

Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

Holmsten, Karin; Eknert, Johanna; Ofverholm, Elisabeth; Papantoniou, Dimitrios et al.

Ingår i Clinical Genitourinary Cancer, 2023

• DOI för Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
• Ladda ner fulltext (pdf) av Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

Lindberg, Åsa; Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne et al.

Ingår i Hematological Oncology, s. 23-31, 2022

• DOI för Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience
• Ladda ner fulltext (pdf) av Pre-treatment health-related quality of life parameters have prognostic impact in patients > 65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience

Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres

Stenman, Maria; Staehler, Michael; Szabados, Bernadett; Sandström, Per et al.

Ingår i Acta Oncologica, s. 306-312, 2019

• DOI för Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres
• Ladda ner fulltext (pdf) av Metastatic papillary renal cell carcinoma in the era of targeted therapy: a retrospective study from three European academic centres

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne; Laurell, Anna et al.

Ingår i Haematologica, 2018

• DOI för Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
• Ladda ner fulltext (pdf) av Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Jerkeman, Mats; Eskelund, Christian Winther; Hutchings, Martin; Raty, Riikka et al.

Ingår i Tha Lancet Haematology, 2018

• DOI för Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.

Laurell, Anna; Lönnemark, Maria; Brekkan, Einar; Magnusson, Anders et al.

Ingår i Journal for ImmunoTherapy of Cancer, 2017

• DOI för Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
• Ladda ner fulltext (pdf) av Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.

Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Kolstad, Arne; Pedersen, Lone Bredo; Eskelund, Christian W.; Husby, Simon et al.

Ingår i Biology of blood and marrow transplantation, s. 428-435, 2017

• DOI för Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

Hellström, Vivan; Tufveson, Gunnar; Wallgren, AnnaCarin; Loskog, Angelica et al.

Ingår i American Journal of Transplantation, s. 472-472, 2017

• DOI för Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation

15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

Eskelund, Christian W.; Kolstad, Arne; Jerkeman, Mats; Raty, Riikka et al.

Ingår i British Journal of Haematology, s. 410-418, 2016

• DOI för 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Albertsson-Lindblad, Alexandra; Kolstad, Arne; Laurell, Anna; Raty, Riikka et al.

Ingår i Blood, s. 1814-1820, 2016

• DOI för Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study

Hellström, Vivan; Enström, Ylva; von Zur-Mühlen, Bengt; Hagberg, Hans et al.

Ingår i Acta Oncologica, s. 774-781, 2016

• DOI för Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials

Hoster, E.; Geisler, C. H.; Doorduijn, J.; van der Holt, B. et al.

Ingår i Leukemia, s. 1428-1430, 2016

• DOI för Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials

miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Husby, Simon; Ralfkiaer, Ulrik; Garde, Christian; Zandi, Roza et al.

Ingår i Blood, s. 2669-2677, 2015

• DOI för miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator

Long-term survival in unfavorable-risk mRCC patients after intratumoral administration of a cell-based allogeneic vaccine adjuvant.

Magnusson, Anders; Wallgren, AnnaCarin; Brekkan, Einar; Lönnemark, Maria et al.

Ingår i Journal of Clinical Oncology, 2015

Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

Farnebo, Jacob; Gryback, Per; Harmenberg, Ulrika; Laurell, Anna et al.

Ingår i BMC Cancer, s. 408, 2014

• DOI för Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
• Ladda ner fulltext (pdf) av Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma

Stenman, Maria; Laurell, Anna; Lindskog, Magnus

Ingår i Medical Oncology, s. 841, 2014

• DOI för Prognostic significance of serum albumin in patients with metastatic renal cell carcinoma

Nordic MCL-3 study: ⁹⁰Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

Kolstad, Arne; Laurell, Anna; Jerkeman, Mats; Grønbæk, Kirsten et al.

Ingår i Blood, s. 2953-2959, 2014

• DOI för Nordic MCL-3 study: ⁹⁰Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma

One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

Tandstad, T.; Stahl, O.; Hakansson, U.; Dahl, O. et al.

Ingår i Annals of Oncology, s. 2167-2172, 2014

• DOI för One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma: a Nordic Lymphoma Group study

Nordström, Lena; Sernbo, Sandra; Eden, Patrik; Grønbaek, Kirsten et al.

Ingår i British Journal of Haematology, s. 98-108, 2014

• DOI för SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma: a Nordic Lymphoma Group study

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

Laurell, Anna; Kolstad, Arne; Jerkeman, Mats; Raty, Riikka et al.

Ingår i Leukemia and Lymphoma, s. 1206-1208, 2014

• DOI för High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials

Husby, Simon; Pedersen, Lone Bredo; Ralfkiaer, Ulrik; Garde, Christian et al.

Ingår i Blood, 2014

High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer: a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA)

Haugnes, Hege S.; Laurell, Anna; Stierner, Ulrika; Bremnes, Roy M. et al.

Ingår i Acta Oncologica, s. 168-176, 2012

• DOI för High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer: a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA)

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur

Geisler, Christian H.; Kolstad, Arne; Laurell, Anna; Jerkeman, Mats et al.

Ingår i British Journal of Haematology, s. 355-362, 2012

• DOI för Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur

Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients < 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin

Arne, Kolstad; Laurell, Anna; Jerkeman, Mats; Gronbaek, Kirsten et al.

Ingår i Blood, s. 747, 2012

Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group

Tandstad, Torgrim; Smaaland, Rune; Solberg, Arne; Bremnes, Roy M. et al.

Ingår i Journal of Clinical Oncology, s. 719-725, 2011

• DOI för Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group

Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group

Olofsson, Sven-Erik; Tandstad, Torgrim; Jerkeman, Mats; Dahl, Olav et al.

Ingår i Journal of Clinical Oncology, s. 2032-2039, 2011

• DOI för Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group

Impact of TP53 mutation and 17p deletion in mantle cell lymphoma

Halldórsdóttir, Anna Margret; Lundin, A; Murray, Fiona; Mansouri, Larry et al.

Ingår i Leukemia, 2011

• DOI för Impact of TP53 mutation and 17p deletion in mantle cell lymphoma

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Geisler, Christian H.; Kolstad, Arne; Laurell, Anna; Räty, Riikka et al.

Ingår i Blood, s. 1530-1533, 2010

• DOI för The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Hess, Georg; Herbrecht, Raoul; Romaguera, Jorge; Verhoef, Gregor et al.

Ingår i Journal of Clinical Oncology, s. 3822-3829, 2009

• DOI för Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Genome-wide microarray-based comparative genomic hybridization analysis of lymphoplasmacytic lymphomas reveals heterogeneous aberrations

Buckley, Patrick G.; Walsh, Sarah H.; Laurell, Anna; Sundström, Christer et al.

Ingår i Leukemia and Lymphoma, s. 1528-34, 2009

• DOI för Genome-wide microarray-based comparative genomic hybridization analysis of lymphoplasmacytic lymphomas reveals heterogeneous aberrations

Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma

Flordal Thelander, Emma; Ichimura, Koichi; Collins, V. Peter; Walsh, Sarah H. et al.

Ingår i Leukemia Research, s. 1219-1230, 2007

• DOI för Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma

Telomere length and correlation with histopathogenesis in B-cell leukemias/lymphomas

Walsh, Sarah H.; Grabowski, Pawel; Berglund, Mattias; Thunberg, Ulf et al.

Ingår i European Journal of Haematology, s. 283-289, 2007

• DOI för Telomere length and correlation with histopathogenesis in B-cell leukemias/lymphomas

Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status.

Thorselius, Mia; Kröber, Alexander; Murray, Fiona; Thunberg, Ulf et al.

Ingår i Blood, s. 2889-94, 2006

Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14).

Adde, Magdalena; Enblad, Gunilla; Hagberg, Hans; Sundström, Christer et al.

Ingår i Med Oncol, s. 283-93, 2006

Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or V(H) gene mutation status in chronic lymphocytic leukaemia.

Tobin, Gerard; Skogsberg, Åsa; Thunberg, Ulf; Laurell, Anna et al.

Ingår i Leukemia, s. 871-873, 2005

Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.

Tobin, Gerard; Thunberg, Ulf; Laurell, Anna; Karlsson, Karin et al.

Ingår i Haematologica, s. 465-9, 2005

Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes.

Thelander, Emma Flordal; Walsh, Sarah H; Thorselius, Mia; Laurell, Anna et al.

Ingår i Mod Pathol, s. 331-9, 2005

Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status.

Grabowski, Pawel; Hultdin, Magnus; Karlsson, Karin; Tobin, Gerard et al.

Ingår i Blood, s. 4807-12, 2005

VH gene mutation status and cellular drug resistance in chronic lymphocytic leukemia

Åleskog, Anna; Tobin, Gerard; Laurell, Anna; Thunberg, Ulf et al.

Ingår i Eur J Haematol, s. 407-411, 2004

Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia.

Tobin, Gerard; Thunberg, Ulf; Karlsson, Karin; Murray, Fiona et al.

Ingår i Blood, s. 2879-85, 2004